Praxis Precision Medicines jumped 24% premarket after its epilepsy drug relutrigine delivered strong interim results, prompting the DMC to stop the EMBOLD trial early. The therapy targets severe genetic epilepsy syndromes with no approved treatments. Retail sentiment turned extremely bullish as message volume spiked. Praxis will present topline data on Dec 6 at the AES meeting.